This year, decisions from the courts, FDA or DOJ could all shut down telehealth for medication abortion, which is how most people in states with bans get care.
Articles on Abortion medication
Displaying all articles
Mifepristone’s safety in medication abortions has been well established over more than two decades, but legal wrangling leaves the future of the drug hanging in the balance.
The Supreme Court’s ruling on mifepristone keeps the drug accessible for now, but its future is still in limbo.
If the ruling to reverse the use of mifepristone stands, it will not only severely restrict abortion access for women throughout the US – it will have far-reaching effects on health care.
The FDA’s allowance for pharmacies to dispense mifepristone will broaden access to the two-pill mifepristone-misoprostol regimen of medication abortion, which is 95% to 98% effective.
Top contributors
-
Associate Professor of Legal Studies and Political Science, UMass Amherst
-
Associate Professor of Family Medicine, School of Medicine, University of Washington
-
Associate Professor of Obstetrics, Gynecology and Gynecologic Surgery, University of California, San Francisco
-
Professor of Law, The University of Texas at Austin